706 related articles for article (PubMed ID: 10477550)
1. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
[TBL] [Abstract][Full Text] [Related]
2. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype.
D'Souza S; Rimoldi D; Líenard D; Lejeune F; Cerottini JC; Romero P
Int J Cancer; 1998 Dec; 78(6):699-706. PubMed ID: 9833762
[TBL] [Abstract][Full Text] [Related]
3. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
Anichini A; Mortarini R; Maccalli C; Squarcina P; Fleischhauer K; Mascheroni L; Parmiani G
J Immunol; 1996 Jan; 156(1):208-17. PubMed ID: 8598464
[TBL] [Abstract][Full Text] [Related]
5. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
6. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
7. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
[TBL] [Abstract][Full Text] [Related]
8. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
[TBL] [Abstract][Full Text] [Related]
9. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
10. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
[TBL] [Abstract][Full Text] [Related]
11. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
[TBL] [Abstract][Full Text] [Related]
12. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro.
Ostankovitch M; Le Gal FA; Connan F; Chassin D; Choppin J; Guillet JG
Int J Cancer; 1997 Sep; 72(6):987-94. PubMed ID: 9378563
[TBL] [Abstract][Full Text] [Related]
13. Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.
Ghosh S; Rosenthal R; Zajac P; Weber WP; Oertli D; Heberer M; Martin I; Spagnoli GC; Reschner A
Ann Surg; 2005 Dec; 242(6):851-7, discussion 858. PubMed ID: 16327495
[TBL] [Abstract][Full Text] [Related]
14. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.
Pittet MJ; Valmori D; Dunbar PR; Speiser DE; Liénard D; Lejeune F; Fleischhauer K; Cerundolo V; Cerottini JC; Romero P
J Exp Med; 1999 Sep; 190(5):705-15. PubMed ID: 10477554
[TBL] [Abstract][Full Text] [Related]
15. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
Mandruzzato S; Rossi E; Bernardi F; Tosello V; Macino B; Basso G; Chiarion-Sileni V; Rossi CR; Montesco C; Zanovello P
J Immunol; 2002 Oct; 169(7):4017-24. PubMed ID: 12244204
[TBL] [Abstract][Full Text] [Related]
16. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors.
Mortarini R; Anichini A; Di Nicola M; Siena S; Bregni M; Belli F; Molla A; Gianni AM; Parmiani G
Cancer Res; 1997 Dec; 57(24):5534-41. PubMed ID: 9407964
[TBL] [Abstract][Full Text] [Related]
17. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides.
Jäger E; Maeurer M; Höhn H; Karbach J; Jäger D; Zidianakis Z; Bakhshandeh-Bath A; Orth J; Neukirch C; Necker A; Reichert TE; Knuth A
Int J Cancer; 2000 May; 86(4):538-47. PubMed ID: 10797269
[TBL] [Abstract][Full Text] [Related]
18. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
[TBL] [Abstract][Full Text] [Related]
19. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
[TBL] [Abstract][Full Text] [Related]
20. Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients.
Palermo B; Campanelli R; Mantovani S; Lantelme E; Manganoni AM; Carella G; Da Prada G; della Cuna GR; Romagne F; Gauthier L; Necker A; Giachino C
Eur J Immunol; 2001 Feb; 31(2):412-20. PubMed ID: 11180105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
